ARCTICZYMES TECHNOLOGIES ASA SEB Healthcare Seminar
CEO Michael Akoh
Agenda
1 | At a glance |
2 Markets
3 | Our customers |
4 Products and pipeline
5 Spotlight: SAN
6 Financial performance
ArcticZymes Technologies
Shaped by the Arctic - global outreach
HQ in Tromsø, Norway
World class commercial supplier of novel and high-quality enzymes
ISO 13485 certified and manufacturing according to GMP guidelines
20+ years' experience
65+ employees
Direct sales in most markets
Publicly listed, OSE:AZT
Offices/Labs
Logistic Hubs
3
On a Mission
Focused and partner driven strategy
A global leading specialist enzymes partner within Advanced Therapies and Molecular Diagnostics
Be a catalyst for innovation and value creation for our partners
4
A Growing Market
Targeting high-growth Biomanufacturing and Molecular diagnostics segments
Biomanufacturing
Focus on Cell & Gene Therapies
Market Size 2023 - 2030
5 Bil USD - 30 Bil USD
Nucleases 500 million US dollars
(CAGR 20%)
Bio-manufacturing
- Enzymes utilized in the production process of gene therapy
- FDA expects more 200 INDs/year and 10- 20 approvals/year from 2025 within CGT
Molecular diagnostics
Enzymes for driving assay technologies and innovation
- New technologies and chemistry driving growth
Molecular Tools
Molecular Research & Diagnostics
Market Size 2023 - 2027
23 - 30 Bil USD (CAGR. 5.4%)
5
B2B Value chain
Biomanufacturing and Molecular Tools customers
"Biomanufacturing"
Customer
Pharma / CDMO
ArcticZymes | over 300 Business-to-Business (B2B) customers |
Technologies | |
Component partner |
Customer
Diagnostics
"Molecular Tools"
Hospitals
Laboratories
Researchers
End-users
100,000s scientists,
doctors, clinics
6
Our Solutions
Unique enzymes for applications in the workflow
Molecular Tools (Molecular Diagnostics & Research) | Biomanufacturing (Therapeutics) |
IsoPol™ | SAN (Salt Active | M-SAN HQ | ||||||
Shrimp Alkaline | Cod Uracil DNA | Ligases | Proteinases | |||||
Phosphatase | Glycosylase | Polymerases | Nuclease) HQ family | |||||
Endo- & Exo- | Reverse | DNA | |||||
Transcriptases | Polymerases | ||||||
Nucleases | |||||||
Nucleic Acid Extraction, Amplification and Sequencing | Cell & Gene therapy (viral vectors); RNA therapeutics |
technologies | (mRNA vaccines) |
Building out the product portfolio
Looking further ahead - beyond 2023
*
- Expand Biomanufacturing capabilities
- SAN product lifecycle management
-
Value through Quality - Transitions & DMF o RNA therapeutics - generic & novel
o Nucleases and Proteinases
-
Value through Quality - Transitions & DMF o RNA therapeutics - generic & novel
- Expand Molecular Tools capabilities
-
Complete MDx workflow assembly o Expand to NGS variants
o Push new RT and Taq ++ o Hot Start / Formulations
8* Forward looking slide - Project risks - Timelines & Business Case subject to change
SAN
Salt Active
Nuclease
Product Placement - Biomanufacturing
Case Study - viral vector manufacturing (CGT)
high salt matrix high viscosity
impure viral vector
+
a "soup" of
broken cell fragments
| ||||
SAN HQ | | ? | SAN HQ | ✓ |
Nuclease | ELISA | |||
digestion |
viral vector manufacturing workflow (multi-step)
Remove unwanted nucleic acids
Reduce viscosity
SAN HQ | |
removal | |
✓ efficient nuclease (viscosity) | |
SAN HQ | ✓ low temp (sensitivity) |
unique | ✓ tolerant to high salt (aggregation) |
properties | ✓ tolerant to high salt (digestion) |
✓ high pI - charged (easy removal) |
pure
viral vector
("Drug")
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
ArcticZymes Technologies ASA published this content on 22 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 December 2023 11:44:18 UTC.
